OncoTarget® Myeloid68
An NGS-Based Test for Myeloid Leukemia
What is OncoTarget® Myeloid68?
Myeloid68 uses targeted next-generation sequencing (NGS) to detect somatic alterations in 68 genes associated with myeloid malignancies. With full coverage of the coding regions of each gene, this comprehensive myeloid panel can provide actionable results for diagnosis, prognosis, therapy, and monitoring.
Hematopoiesis is a wonder of life. With the volume of a two-liter bottle, the prolific cells of the bone marrow produce one billion cells per hour to keep up with the needs of the body. This lifetime of staggering production does have its costs.
Our hematopoietic genomes accumulate on average 14 somatic mutations per year of life, and although a vast majority of these are silent, a few may be detrimental. These harmful mutations result in a variety of myeloid diseases, and they may be acutely or chronically pathogenic, depending on how fast they impair hematopoiesis.
GoPath’s Myeloid68 panel evaluates 68 genes for mutations associated with a variety of myeloid abnormalities including myeloproliferative neoplasms (MPNs), clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and chronic myelomonocytic leukemia (CMML). This panel is essential for the complete molecular characterization of your myeloid diseases.
Our hematopoietic genomes accumulate on average 14 somatic mutations per year of life, and although a vast majority of these are silent, a few may be detrimental. These harmful mutations result in a variety of myeloid diseases, and they may be acutely or chronically pathogenic, depending on how fast they impair hematopoiesis.
GoPath’s Myeloid68 panel evaluates 68 genes for mutations associated with a variety of myeloid abnormalities including myeloproliferative neoplasms (MPNs), clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and chronic myelomonocytic leukemia (CMML). This panel is essential for the complete molecular characterization of your myeloid diseases.
Comprehensive and Targeted Panel of Genes
Myeloid disease
Myeloproliferative Neoplasms (MPNs)
Genes: JAK2, CALR, MPL, ASXL1, CSF3R, SETBP1, KIT, ABL1
Myeloid disease
Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Clonal Cytopenia of Undetermined Significance (CCUS)
Genes: TET2, SRSF2, ASXL1, ZRSR2, DNMT3A, U2AF1, IDH1, IDH2, KDM6A, SF3B1, JAK2, CSF3R, KRAS, NRAS, TP53, BCOR, STAG2, PHF6, RUNX1, RAD21, SETBP1
Myeloid disease
Myelodysplastic Syndrome (MDS)
Genes: TET2, SRSF2, ASXL1, ZRSR2, DNMT3A, U2AF1, IDH1, IDH2, SF3B1, KRAS, NRAS, JAK2, WT1,TP53, BCOR, STAG2
Myeloid disease
Acute Myeloid Leukemia (AML)
Genes: FLT3, CEBPA, TP53, DNMT3A, IDH1, IDH2, ASXL1, RUNX1, WT1, NPM1, TET2, JAK2, KRAS, NRAS, KIT, PTPN11, KMT2A, EZH2, GATA2, SRSF2, U2AF1, SF3B1, RAD21, STAG2, SMC1A, SMC3, BCOR, PHF6, SETBP1, ETV6, ETNK1
Myeloid disease
Chronic Myelomonocytic Leukemia (CMML)
Genes: SRSF2, ASXL1, TET2, SETBP1
